Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peficitinib - Astellas Pharma

Drug Profile

Peficitinib - Astellas Pharma

Alternative Names: ASP-015K; ASP-015K hydrobromide; JNJ-54781532; Peficitinib hydrobromide; Smyraf

Latest Information Update: 01 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Class Adamantanes; Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Immunosuppressants; Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Discontinued Plaque psoriasis; Transplant rejection; Ulcerative colitis

Most Recent Events

  • 31 Oct 2019 Astellas Pharma plans a phase I trial for Healthy volunteers in China (PO) in October 2019 (NCT04143477)
  • 10 Jul 2019 Launched for Rheumatoid arthritis in Japan (PO)
  • 12 Jun 2019 Safety, efficacy and pharmacokinetics data from a phase I trial in Healthy volunteers and impaired Renal functional presented at the 20th Annual Congress of the European League Against Rheumatism (EULAR-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top